Trial Profile
A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Apr 2021
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Astex Pharmaceuticals
- 24 Aug 2017 Additional group of patients with 10 day schedule was added as per protocol amendment.
- 24 Aug 2017 Results (n=107, data cut off June 13, 2016) of final analysis of phase II study published in the Lancet Oncology
- 20 Apr 2016 Results of preliminary analysis (n=23) presented at the 107th Annual Meeting of the American Association for Cancer Research